Pharma Giant's Q1 Earnings: Solid Growth & Promising Pipeline

Pharma giants Q1 earnings soar: Total revenues hit $3.5 billion, up 3% from last year, with adjusted EBITDA at $1 billion and adjusted earnings per share at $0.59. CEO Scott Smith attributes success to a three-part strategy, with Greater China leading the charge at 18% growth. Japan is heating up with new approvals and launches. The pipeline is buzzing with fast-acting meloxicam NDA accepted, low-dose Xulane patch PDUFA July 30th, and eye care drops eyed for October approval. Analysts are hyped about cleaner quarters and durable growth, with questions on Chinas momentum and top pipeline bets. New data shows Creon in Europe needs higher doses for better control, and Selatogrel trial enrolling 1,200 patients monthly. Generics are rolling strong, with Abilify Maintena approved for U.S. launch soon. The company is poised to hit or beat full-year targets, fueling dividends, buybacks, and pipeline firepower. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0667cbfa1aad39fb